Wedbush is removing Argenx (ARGX) from the firm’s Best Ideas List. Wedbush remains constructive on the name, but believes the upside isn’t compelling enough to warrant inclusion on the BIL.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx: Strong Market Position and Growth Potential Justify Buy Rating
- Argenx price target raised to $925 from $830 at JPMorgan
- Promising Outlook for arGEN X: Robust Sales Projections and Strategic Expansion Drive Positive Risk-Reward Balance
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly
- Argenx announces Health Canada approval of Vyvgart in CIDP